Emergent BioSolutions (EBS) Competitors $7.72 -1.55 (-16.72%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends EBS vs. LGND, MNKD, DVAX, CLDX, BCRX, MYGN, NVAX, INVA, OPK, and IRWDShould you be buying Emergent BioSolutions stock or one of its competitors? The main competitors of Emergent BioSolutions include Ligand Pharmaceuticals (LGND), MannKind (MNKD), Dynavax Technologies (DVAX), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Myriad Genetics (MYGN), Novavax (NVAX), Innoviva (INVA), OPKO Health (OPK), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "biotechnology" industry. Emergent BioSolutions vs. Ligand Pharmaceuticals MannKind Dynavax Technologies Celldex Therapeutics BioCryst Pharmaceuticals Myriad Genetics Novavax Innoviva OPKO Health Ironwood Pharmaceuticals Ligand Pharmaceuticals (NASDAQ:LGND) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends. Which has stronger valuation and earnings, LGND or EBS? Ligand Pharmaceuticals has higher earnings, but lower revenue than Emergent BioSolutions. Emergent BioSolutions is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLigand Pharmaceuticals$152.42M13.85$52.15M$2.5144.51Emergent BioSolutions$1.09B0.38-$760.50M-$4.10-1.88 Do analysts rate LGND or EBS? Ligand Pharmaceuticals presently has a consensus target price of $144.83, indicating a potential upside of 29.65%. Emergent BioSolutions has a consensus target price of $14.00, indicating a potential upside of 81.35%. Given Emergent BioSolutions' higher probable upside, analysts clearly believe Emergent BioSolutions is more favorable than Ligand Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ligand Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Emergent BioSolutions 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more risk and volatility, LGND or EBS? Ligand Pharmaceuticals has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Does the MarketBeat Community favor LGND or EBS? Ligand Pharmaceuticals received 128 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. Likewise, 70.62% of users gave Ligand Pharmaceuticals an outperform vote while only 66.88% of users gave Emergent BioSolutions an outperform vote. CompanyUnderperformOutperformLigand PharmaceuticalsOutperform Votes54870.62% Underperform Votes22829.38% Emergent BioSolutionsOutperform Votes42066.88% Underperform Votes20833.12% Do institutionals & insiders have more ownership in LGND or EBS? 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.4% of Emergent BioSolutions shares are owned by institutional investors. 5.9% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 1.2% of Emergent BioSolutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor LGND or EBS? In the previous week, Ligand Pharmaceuticals had 6 more articles in the media than Emergent BioSolutions. MarketBeat recorded 8 mentions for Ligand Pharmaceuticals and 2 mentions for Emergent BioSolutions. Ligand Pharmaceuticals' average media sentiment score of 0.71 beat Emergent BioSolutions' score of 0.29 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Emergent BioSolutions 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is LGND or EBS more profitable? Ligand Pharmaceuticals has a net margin of 29.68% compared to Emergent BioSolutions' net margin of -18.55%. Ligand Pharmaceuticals' return on equity of 4.95% beat Emergent BioSolutions' return on equity.Company Net Margins Return on Equity Return on Assets Ligand Pharmaceuticals29.68% 4.95% 4.39% Emergent BioSolutions -18.55%-9.91%-3.31% SummaryLigand Pharmaceuticals beats Emergent BioSolutions on 15 of the 18 factors compared between the two stocks. Ad WealthPressThe only candlestick pattern worth a darnIt’s widely known that 80% of daily market action is driven by Wall Street algorithms… Now, most people think of the algorithms are “bad” When in reality, they are neither good nor bad… They are simply programmed to buy and sell certain stocks over and over again… But here is the thing… They are predictable… They typically buy the same stocks at the same levels over and over again…Follow this link here and enter your email address to sign up… Get Emergent BioSolutions News Delivered to You Automatically Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EBS vs. The Competition Export to ExcelMetricEmergent BioSolutionsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$418.30M$6.38B$5.07B$19.79BDividend YieldN/A8.08%5.10%3.50%P/E Ratio-1.8810.51100.6041.87Price / Sales0.38244.531,195.1320.82Price / Cash11.3453.4941.0321.65Price / Book0.829.306.344.66Net Income-$760.50M$154.14M$119.64M$983.45M7 Day Performance-34.41%-9.47%-5.13%-2.12%1 Month Performance-15.54%-7.30%-2.72%-0.39%1 Year Performance276.59%28.21%31.10%23.34% Emergent BioSolutions Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EBSEmergent BioSolutions4.4029 of 5 stars$7.72-16.7%$14.00+81.3%+264.2%$418.30M$1.09B-1.881,600Analyst UpgradeGap DownLGNDLigand Pharmaceuticals4.9911 of 5 stars$120.30-2.6%N/A+95.5%$2.20B$152.42M47.9380Analyst ForecastMNKDMannKind3.9359 of 5 stars$7.22flatN/A+88.9%$1.99B$198.96M103.14400DVAXDynavax Technologies4.6463 of 5 stars$13.50-1.2%N/A-9.8%$1.77B$249.69M103.85408Short Interest ↑CLDXCelldex Therapeutics2.7989 of 5 stars$26.34+0.5%N/A-15.3%$1.75B$9.98M-10.25160Insider BuyingBCRXBioCryst Pharmaceuticals4.2114 of 5 stars$7.86-4.0%N/A+36.8%$1.63B$331.41M-12.89530Short Interest ↓MYGNMyriad Genetics4.3033 of 5 stars$16.37-5.4%N/A-11.4%$1.49B$802.20M-12.592,700Analyst UpgradeNews CoverageNVAXNovavax3.7314 of 5 stars$8.45-6.2%N/A+25.6%$1.35B$560.34M-3.061,543Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageINVAInnoviva1.35 of 5 stars$20.37+1.2%N/A+38.5%$1.27B$352.75M29.52112News CoverageOPKOPKO Health4.6578 of 5 stars$1.61+2.5%N/A+14.7%$1.12B$863.50M-8.473,930Insider BuyingIRWDIronwood Pharmaceuticals4.2073 of 5 stars$4.43-7.3%N/A-55.4%$707.65M$442.73M-147.67220Analyst DowngradeShort Interest ↓ Related Companies and Tools Related Companies LGND Alternatives MNKD Alternatives DVAX Alternatives CLDX Alternatives BCRX Alternatives MYGN Alternatives NVAX Alternatives INVA Alternatives OPK Alternatives IRWD Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:EBS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent BioSolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emergent BioSolutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
